p53 in malignant glioma: 20 years later and still much to learn
Journal Title: Neuro-Oncology - Year 2010, Vol 12, Issue 5
Abstract
Authors and Affiliations
C. David James
Keywords
Related Articles
- EP ID EP679600
- DOI 10.1093/neuonc/noq037
- Views 24
- Downloads 0
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial
The aim of this clinical trial was to investigate safety and efficacy when combining cetuximab with bevacizumab and irinotecan in patients with recurrent primary glioblastoma multiforme (GBM). Patients were included with...
Human umbilical cord blood stem cells show PDGF-D–dependent glioma cell tropism in vitro and in vivo
Despite advances in clinical therapies and technologies, the prognosis for patients with malignant glioma is poor. Neural stem cells (NSCs) have a chemotactic tropism toward glioma cells. The use of NSCs as carriers of t...
A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors
Glial tumors with oligodendroglial components are considered chemo-responsive. Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29 anaplastic oligoastrocytomas [OA]) were enrolled into this multi...
Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors—towards individualized tumor treatment?
The purpose of this study was to determine whether chromosome 10q loss is a predictor of tumor aggressiveness and poor clinical outcome in patients with oligodendroglial tumors alone or together with loss of heterozygosi...
Genetic variants in inflammation pathway genes and asthma in glioma susceptibility
Single nucleotide polymorphisms (SNPs) in inflammation-related genes have previously been shown to alter risks of developing various cancers. However, the effects of such SNPs on glioma risk remain unclear. We used a mul...